Keytruda Cost in 2026: What You’ll Actually Pay (Latest U.S. Data & Savings Tips)
In 2026, the real cost of Keytruda (pembrolizumab) continues to rise across the U.S., with list prices now reaching $11,564 per 200 mg dose or $23,590 for the 400 mg / 6-week schedule. While insurance coverage, assistance programs, and Medicare options can significantly reduce out-of-pocket costs, many American patients still face bills ranging from $1,200 to $10,000 per month, depending on their plan. This article breaks down updated Keytruda pricing data for 2026, compares infusion costs by hospital and pharmacy, explains copay assistance options, and provides the latest policy updates about potential government price negotiations. You’ll also find detailed FAQs addressing what patients in the U.S. are actually paying, how insurance affects coverage, and where to find verified cost-saving programs. Read on to discover the latest Keytruda prices, insurance breakdowns, and patient support options available in 2026.
Read More
